The Market Opportunity

The Doxil is currently marketed in the US by a few number of companies.
Although the patent protection lapsed in 2010, there is a high barrier of entry for new players, due to the high complexity of the manufacturing process. In light of this, combined with the growth of the market and the addition of new indications for the drug, the selling prices have remained relatively stable during this time – in opposed to the normal cycle of a generic drug.

Due to high demand and low competition with high barriers of entry, Ayana’s generic Doxil is expected to be able to rapidly penetrate the Doxil market in the US and establish meaningful revenues, with high profit margins.